Gastroenterologists favorably view Janus kinase (JAK) inhibitors for utilization in treating inflammatory bowel disease (IBD), according to a recent survey conducted by Decision Resources Group.
Gastroenterologists favorably view Janus kinase (JAK) inhibitors for utilization in treating inflammatory bowel disease (IBD), according to a recent survey conducted by Decision Resources Group.
The results of the “Ulcerative Colitis/Crohn’s Disease: US Access & Reimbursement” survey also suggested that a majority of payers recognize Pfizer’s Xeljanz (tofacitinib) and Gilead/Galapagos’ filgotinib as upcoming therapies for treating ulcerative colitis and Crohn’s disease, according to the report. Gastroenterologists predict that these therapies will be prescribed within their first year on the market.
Johnson & Johnson’s Remicade (infliximab) was also found to be prevalent in the market despite the introduction of the infliximab biosimilar, Pfizer’s Inflectra, to the market. However, it is predicted that payers will push biosimilars to encourage their use through implementing utilization management approaches.
Additional key findings from the survey include:
"Drug makers looking to compete in the IBD market need to overcome the entrenched favorable reimbursement status of the long-marketed TNF inhibitors,” Brian Nasipak, an analyst with Decision Resources Group, said in a statement. “That said, gastroenterologists are excited about the JAK inhibitors' potential in a market where many patients are refractory to treatments already available although use may be relegated to later lines."
The report was intended to bring insight into the impact of payer policy on physician prescribing behavior. Overall, the results reveal how gastroenterologists ultimately favor JAK inhibitors to treat IBD.
"At this time there is little evidence to suggest that Remicade's market access position has suffered with the launch of biosimilar infliximab. J&J has had time to prepare for the biosimilar's launch and, at least for now, appears to have protected its place in the IBD market,” Nasipak concluded. “We will be watching carefully to see how long they can maintain their position and to see what levels of discounting and rebates are needed to do so."
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More